STOCK TITAN

Tenon Medical, Inc. Sets Date for First Quarter 2026 Earnings

(Neutral)
(Neutral)
Tags
earnings date

Tenon Medical (NASDAQ:TNON) will release first quarter 2026 financial results for the period ended March 31, 2026 after market close on Tuesday, May 12, 2026. The company will host a conference call at 4:30 p.m. Eastern Time the same day with a Q&A session.

Dial-in numbers, international access, a webcast, and an audio replay available through May 26, 2026 are provided; the telephone replay access code is 13759830.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction – TNON

+2.40%
+2.40% Session close to close

In the May 1 session, TNON gained 2.40%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timetable for Tenon’s Q1 2026 results, with a call on May 12, 2026 at 4:3...
Analysis

This announcement sets the timetable for Tenon’s Q1 2026 results, with a call on May 12, 2026 at 4:30 p.m. ET. Earlier communications paired earnings dates with preliminary revenue ranges, while recent filings detailed PIPE equity and convertible note financings plus going-concern language. Investors watching this update may focus on upcoming Q1 metrics, cash balance trends, and any commentary on commercialization progress and financing needs.

Key Figures

Earnings release date: May 12, 2026 Conference call time: 4:30 p.m. Eastern Time US dial-in: 1-877-407-0792 +5 more
8 metrics
Earnings release date May 12, 2026 Q1 2026 financial results release after market close
Conference call time 4:30 p.m. Eastern Time Q1 2026 earnings conference call start time
US dial-in 1-877-407-0792 Domestic access number for earnings call
International dial-in 1-201-689-8263 International access number for earnings call
Replay end date May 26, 2026 End date for audio playback availability
US replay dial-in 1-844-512-2921 Domestic telephone replay number
International replay dial-in 1-412-317-6671 International telephone replay number
Replay access code 13759830 Access code for telephone replay

Previous Earnings date Reports

1 past event · Latest: Feb 05 (Positive)
Same Type Pattern 1 events
Date Event Sentiment 24h Move Catalyst
Feb 05 Earnings date set Positive -2.3% Announced Q4/FY2025 earnings date and reaffirmed revenue ranges with call details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior earnings date news coincided with a modest negative move, suggesting some caution around scheduling/preview announcements.

Recent Company History

Recent disclosures show Tenon combining growth with ongoing financing needs. On Feb 5, 2026, it set the Q4/FY2025 earnings date and reaffirmed revenue ranges, and the stock moved -2.26% over 24 hours. Subsequent filings detailed PIPE and convertible note financings, insider equity activity, and IP expansion. Today’s Q1 2026 earnings date notice continues the pattern of providing call logistics and timing ahead of results.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

LOS GATOS, CA / ACCESS Newswire / May 1, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today announced plans to release financial results for the first quarter ended March 31, 2026 after market close on Tuesday, May 12, 2026. The Company will also hold a conference call on the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with its covering analysts.

Date:

Tuesday, May 12, 2026

Time:

4:30 p.m. Eastern time

Dial-in:

1-877-407-0792

International Dial-in:

1-201-689-8263

Webcast:

TNON Conference Call

Please dial in at least 10 minutes before the start of the call to ensure timely participation.

An audio playback of the call will be available through May 26, 2026, on Tenon's Investor Relations website at http://ir.tenonmed.com/ or via telephone replay by dialing 1-844-512-2921 (USA) or 1-412-317-6671 (International). The access code will be 13759830.

About Tenon Medical, Inc.

Tenon Medical, Inc. is a medical device company founded in 2012 and committed to developing novel technologies for patients suffering from debilitating SI joint pain and dysfunction. The Company markets the Catamaran® and SImmetry+® SI Joint Fusion Systems, which offer a novel, less invasive approach to treating SI joint disease. Together, these platforms uniquely position Tenon with multiple surgical approaches, lateral and inferior-posterior, both designed to be minimally invasive, enable authentic arthrodesis, and supported by robust clinical evidence, including the published prospective Mainsail and EVoluSIon SI joint fusion studies. These differentiated technologies enable physicians to customize treatment plans through an innovative portfolio spanning SI joint fusion, spinal fusion, and deformity adjuncts, each solution engineered to deliver fusion outcomes more reliably. This multi-platform, multiapproach strategy strengthens Tenon's competitive advantage in the expanding SI joint fusion market and underscores the Company's commitment to delivering proven, durable outcomes for physicians and patients. Tenon is focused on three commercial opportunities in the SI joint market: 1) primary SI joint procedures, 2) revision of failed SI joint implants, and 3) augmenting spinal fusion. For more information, please visit www.tenonmed.com.

The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®, Catamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®, Catamaran Transfixation Fusion System®, Catamaran Transfixation Fusion Device®, SImmetry® are registered trademarks of Tenon Medical, Inc. MAINSAILTM, and SImmetry+ are also trademarks of Tenon Medical, Inc.

Investor Contact

Shannon Devine
MZ North America
203-741-8811
tenon@mzgroup.us

SOURCE: Tenon Medical, Inc.



View the original press release on ACCESS Newswire

FAQ

When will Tenon Medical (TNON) report Q1 2026 earnings?

Tenon will report Q1 2026 results after market close on Tuesday, May 12, 2026. According to the company, the release covers the quarter ended March 31, 2026 and will be followed by a conference call at 4:30 p.m. Eastern Time on the same day.

What time is Tenon Medical's (TNON) Q1 2026 conference call on May 12, 2026?

The conference call is scheduled for 4:30 p.m. Eastern Time on May 12, 2026. According to the company, the call will discuss financial results for the quarter ended March 31, 2026 and include a Q&A session with covering analysts.

How can investors access the Tenon Medical (TNON) May 12, 2026 earnings webcast?

Investors can access the webcast via the TNON conference call webcast link on Tenon's investor site. According to the company, the live webcast will stream the May 12 call and an audio playback will be available on the investor relations website through May 26, 2026.

What are the dial-in numbers for Tenon Medical's (TNON) May 12 investor call?

Dial-in for the U.S. is 1-877-407-0792; international dial-in is 1-201-689-8263. According to the company, participants should dial in at least 10 minutes early and a telephone replay is available through May 26, 2026 with access code 13759830.

Will Tenon Medical (TNON) provide a replay of the May 12, 2026 earnings call?

Yes. According to the company, an audio playback will be available on Tenon's investor relations website through May 26, 2026 and by telephone replay at the listed U.S. and international numbers using access code 13759830.

What topics will Tenon Medical (TNON) cover during the May 12, 2026 conference call?

The call will discuss Tenon's first quarter 2026 financial results and conclude with a Q&A session with covering analysts. According to the company, management will review results for the quarter ended March 31, 2026 and answer analyst questions on the same call.